摘要
Hepatitis C virus(HCV)is a common cause of liver disease and is associated with various extrahepatic manifestations(EHMs).This mini-review outlines the currently available treatments for HCV infection and their prognostic effect on hepatic manifestations and EHMs.Direct-acting antiviral(DAA)regimens are considered pan-genotypic as they achieve a sustained virological response(SVR)>85%after 12 wk through all the major HCV genotypes,with high percentages of SVR even in advanced fibrosis and cirrhosis.The risk factors for DAA failure include old males,cirrhosis,and the presence of resistance-associated substitutions(RAS)in the region targeted by the received DAAs.The effectiveness of DAA regimens is reduced in HCV genotype 3 with baseline RAS like A30K,Y93H,and P53del.Moreover,the European Association for the Study of the Liver recommended the identification of baseline RAS for HCV genotype 1a.The higher rate of hepatocellular carcinoma(HCC)after DAA therapy may be related to the fact that DAA regimens are offered to patients with advanced liver fibrosis and cirrhosis,where interferon was contraindicated to those patients.The change in the growth of pre-existing subclinical,undetectable HCC upon DAA treatment might be also a cause.Furthermore,after DAA therapy,the T cell-dependent immune response is much weaker upon HCV clearance,and the down-regulation of TNF-αor the elevated neutrophil to lymphocyte ratio might increase the risk of HCC.DAAs can result in reactivation of hepatitis B virus(HBV)in HCV coinfected patients.DAAs are effective in treating HCV-associated mixed cryoglobulinemia,with clinical and immunological responses,and have rapid and high effectiveness in thrombocytopenia.DAAs improve insulin resistance in 90%of patients,increase glomerular filtration rate,and decrease proteinuria,hematuria and articular manifestations.HCV clearance by DAAs allows a significant improvement in atherosclerosis and metabolic and immunological conditions,with a reduction of major cardiovascular events.They also improve physical function,fatigue,cognitive impairment,and quality of life.Early therapeutic approach with DAAs is recommended as it cure many of the EHMs that are still in a reversible stage and can prevent others that can develop due to delayed treatment.
